[Comment] A new standard for relapsed or refractory follicular lymphoma

Despite progress since 2020, including the approval of immunotherapy as third-line treatment, relapsed or refractory follicular lymphoma remains a clinical challenge, particularly among patients with early progression or resistance to anti-CD20-based regimens. Although the combination of lenalidomide and rituximab is a well established, chemotherapy-free option endorsed by international guidelines, outcomes remain suboptimal in high-risk populations, underscoring the need for novel therapeutic strategies.